ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
De-risking vaccine development: Insights spanning decades of experience
FDA analysis of 40-years of antibacterial development: Dheman et al.
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
The 6 meanings of “Lack of Access” (UNSLAP)
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Reimbursing for innovative antibiotics / Encouraging updates from the AMR conference
FDA workshop: Insights on inhaled antifungals and antibacterials
Modeling the value of an effective antibiotic — Megiddo et al.
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet